Federal contract award
75A50120C00092
US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | ASPR/DAAPPO/ORM HQ |
| NAICS | 325412 — Pharmaceutical Preparation Manufacturing |
| PSC | AN17 — R&D- MEDICAL: BIOMEDICAL (COMMERCIALIZED) |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $696.7M |
| Current contract value | $708.8M |
| Potential contract value / ceiling | $969.8M |
| Start date | May 18, 2020 |
| Current end date | Jan 13, 2027 |
| Potential end date | May 17, 2030 |
| Latest award activity | Sep 2, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 39 of 39 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Sep 2, 2026 | P00038 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PLANNED DEFINITIZATION DATE OF THE CHANGE ORDER ISSUED ON P00022 FROM SEPTEMBER 3, 2026 TO NOVEMBER 3, 2026. |
| Aug 24, 2026 | P00037 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE PLANNED DEFINITIZATION DATE OF THE CHANGE ORDER ISSUED ON P00020 FROM AUGUST 25, 2026 TO SEPTEMBER 29, 2026. |
| Jul 2, 2026 | P00036 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO THE EXTEND THE PLANNED DEFINITIZATION DATE OF THE CHANGE ORDER ISSUED ON P00022 FROM JULY 3, 2026 TO SEPTEMBER 3, 2026. |
| Jun 30, 2026 | P00035 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE THE END DATE OF CLIN 0005 AT NO ADDITIONAL COST TO THE GOVERNMENT |
| Jun 24, 2026 | P00034 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO CHANGE THE PLANNED DEFINITIZATION DATE OF THE CHANGE ORDER ISSUED ON P00020 FROM JUNE 25, 2026 TO AUGUST 25, 2026 |
| May 15, 2026 | P00033 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE POP FOR CLINS 8, 9, AND 11 AT NO ADDITIONAL COST THE GOVERNMENT. |
| Apr 30, 2026 | P00032 | $0 | THE PURPOSE OF THIS ACTION IS TO UPDATE THE PLANNED DEFINITIZATION DATE IN P0022 FROM MAY 3, 2026 TO JULY 3, 2026 |
| Apr 24, 2026 | P00031 | $0 | THE PURPOSE OF THIS ACTION IS TO UPDATE THE PLANNED DEFINITIZATION DATE IN P0020 FROM APRIL 25, 2026 TO JUNE 25, 2026 |
| Mar 3, 2026 | P00030 | $0 | THE PURPOSE OF THIS ACTION IS TO UPDATE THE PLANNED DEFINITIZATION DATE IN P0022 FROM MARCH 3, 2026 TO MAY 3, 2026 |
| Feb 19, 2026 | P00029 | $0 | THE PURPOSE OF THIS ACTION IS TO UPDATE THE PLANNED DEFINITIZATION DATE IN P0025 FROM FEB 25, 2026 TO APRIL 25, 2026 |
| Jan 30, 2026 | P00028 | $0 | THE PURPOSE OF THIS ACTION IS TO EXTEND CLIN 0008 AT NO ADDITIONAL COST TO THE GOVERNMENT |
| Jan 26, 2026 | P00026 | $26.4M | THE PURPOSE OF THIS ACTION IS TO FUND THE REMAINING APIS FOR THE STRATEGIC RESERVE |
| Jan 26, 2026 | P00027 | $53.9M | THE PURPOSE OF THIS ACTION IS TO FUND THE REMAINING APIS FOR THE STRATEGIC RESERVE |
| Jan 5, 2026 | P00025 | $0 | THE PURPOSE OF MODIFICATION P00020 IS TO EXERCISE OPTION CLIN 0010 AND INCORPORATE CHANGES TO THE DESCRIPTION OF SERVICES FOR DOMESTIC PRODUCIBILITY OF ESSENTIAL MEDICINES. |
| Dec 12, 2025 | P00024 | $0 | COR CHANGE |
| Dec 1, 2025 | P00023 | $0 | ADD CLAUSE FAR 52.232-16 PROGRESS PAYMENTS (NOV 2021) ALTERNATE I (MAR 2000) |
| Nov 4, 2025 | P00022 | $25.0M | REVISE THE SCOPE OF EFFORT |
| Oct 23, 2025 | P00021 | $0 | UPDATE POC INFORMATION |
| Sep 30, 2025 | P00020 | $8.4M | THE PURPOSE OF MODIFICATION P00020 IS TO EXERCISE OPTION CLIN 0010 AND INCORPORATE CHANGES TO THE DESCRIPTION OF SERVICES FOR DOMESTIC PRODUCIBILITY OF ESSENTIAL MEDICINES. |
| Aug 27, 2025 | P00019 | $0 | THE PURPOSE OF MODIFICATION P00019 IS TO EXTEND THE CLINS 0003, 0005, 0007, 0008 AT NO ADDITIONAL COST TO THE GOVERNMENT. |
| Jul 22, 2025 | P00018 | $0 | THE PURPOSE OF THIS MOD IS TO UPDATE THE CO FROM ROGER HERNANDEZ TO KIMBERLY GOLDEN |
| Apr 30, 2025 | P00017 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO EXTEND THE BASE PERIOD (CLIN 0003 AND CLIN 0005) AT NO ADDITIONAL COST TO THE GOVERNMENT, UPDATE LANGUAGE IN #4 AND ADD ADDITIONAL MILESTONES IN MILESTONE DELIVERY SCHEDULE, TABLE F.4. PHLOW CORP. - U.S.-BASE |
| Dec 31, 2024 | P00016 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO ISSUE AN EXTENSION. |
| Sep 30, 2024 | P00015 | $7.1M | CLIN 0005 SHALL BE INCREASED FROM $334,423,625.23 BY OBLIGATING $7,095,891.76 TO A CLIN VALUE OF $341,519,516.99. |
| Sep 29, 2024 | P00014 | $3.9M | CLIN 0024 SHALL BE INCREASED FROM $0 BY OBLIGATING $3,892,431.86 TO A CLIN VALUE OF $3,892,431.86. |
| Sep 18, 2024 | P00013 | $52.3M | THE PURPOSE OF THIS MODIFICATION IS TO EXERCISE OPTION PERIOD 2 FOR CLIN 0009 AND CLIN 0010 AT FULL VALUE. |
| Sep 11, 2024 | P00012 | $9.9M | THE PURPOSE OF THIS MODIFICATION IS TO ISSUE AN EXTENSION TO THE BASE PERIOD AND OPTION PERIOD 1, INCREMENTAL FUNDING AND ADDING COST OVERRUN ITEM OF G&A ON DIRECT LABOR. |
| Aug 28, 2024 | P00011 | $7.7M | ADD $7,730,713.39 TO THE TOTAL CONTRACT VALUE: $4,033,088.15 WILL BE ADDED TO CLIN 0003 (U.S.- BASED PRODUCTION OF ACTIVE PHARMACEUTICAL INGREDIENTS (API) FOR COVID 19 MCMS/E |
| Jul 3, 2024 | P00010 | $10.2M | 1. CHANGE THE PERIOD OF PERFORMANCE FOR OPTION PERIOD 1 AT CLIN 0007 FROM 05/18/2024 THROUGH 05/17/2025 TO 07/03/2024 THROUGH 07/02/2025. 2. EXERCISE CLIN 0007 OPTION PERIOD 1 AT THE FULL VALUE OF $19,897,589.16 AND PROVIDE |
| Jun 12, 2024 | P00009 | $0 | 1. CHANGE THE CONTRACTOR ADDRESS. AS A RESULT OF THIS MODIFICATION, BLOCK 8 OF THE SF30 REFLECTS THE UPDATED ADDRESS OF 424 HULL STREET, SUITE 400, RICHMOND, VA 232224-4114. BLOCK 7 OF THE SF26 AWARD DOCUMENT IS HEREBY UPDATED AS W |
| Sep 26, 2023 | P00008 | $50.6M | THE PURPOSE OF MODIFICATION P00008 IS TO: 1. EXTEND THE BASE PERIOD OF PERFORMANCE AT CLINS 0001, 0003, 0004, AND 0005, AT NO ADDITIONAL COST TO THE GOVERNMENT; 2. UPDATE AND CHANGE THE TITLE DESCRIPTIONS OF ALL OPTION PERIOD CLINS, CLINS 0006 THRO |
| Jun 30, 2023 | P00007 | $0 | THE PURPOSE OF MODIFICATION P00007 IS TO ACCEPT THE TRANSFER OF CONTRACT ADMINISTRATION FROM ASPR/BARDA/PCI TO ASPR/IBMSC, AND TO MAKE ADMINISTRATIVE CHANGES TO SECTION G. |
| Jun 28, 2023 | P00006 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO TRANSFER THE CONTRACT FROM ASPR/BARDA/PCI TO ASPR/IBMSC. |
| Apr 24, 2023 | P00005 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO REVISE THE CONTRACT STATEMENT OF OBJECTIVES (SOO) AND TABLE C.1 OF SECTION C.3 STATEMENT OF OBJECTIVES. |
| Jun 16, 2022 | P00004 | $0 | INCORPORATE HHSAR CLAUSE 352.232-71, ELECTRONIC SUBMISSION OF PAYMENT REQUESTS INTO SECTION I OF THE CONTRACT AND TO ALSO EITHER ADD OR UPDATE INVOICE INSTRUCTIONS INTO/IN SECTION G OF THE CONTRACT. |
| Jan 26, 2022 | P00003 | $0 | US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. |
| Dec 21, 2021 | P00002 | $87.0M | US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. |
| Nov 16, 2021 | P00001 | $0 | US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. |
| May 18, 2020 | 0 | $354.3M | US BASED ADVANCED API MANUFACTURING. BASE PERIOD FUNDING FOR US BASED ADVANCED MANUFACTURING OF COVID-19 ESSENTIAL MEDICINES AND FUTURE THREATS. |
Estimated positioning window
May 17, 2029 – Nov 17, 2029
Recompete signal: . Rule-based research score; positioning dates are estimates.
35/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 35/100. Available recorded signals: 30 points.
- Contract end 2030-05-17 (1300 days from calculation)
- +5 points
- 1 historical awards in this buyer and category group
- +0 points
- 39 recorded award transactions
- +10 points
- Latest award action: 2026-09-02
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-10-25 10:18:04.631876+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Oct 25, 2026.
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.